September 2021 - Page 9 of 14

WednesdaySep 15, 2021 1:17 pm

InnerScope Hearing Technologies Inc. (INND) Brings “Direct-to-Consumer Hearing Technology,” Poised to Disrupt Notoriously Underserved Hearing Aid Market

Hearing aids are prohibitively expensive for millions of Americans due to market concentration and the requirement that people must see a medical professional before purchasing hearing aids INND's marketing strategy brings the "Direct to Consumer" model to the hearing aid market amid growing recognition that the current traditional model may not be sustainable Matthew Moore, company's CEO, was featured on New to the Street, explaining how the company is committed to helping people get the hearing aids they need at significantly lower costs In a recent feature on New to the Street, Matthew Moore, InnerScope Hearing Technologies (OTC: INND)’s CEO,…

WednesdaySep 15, 2021 12:38 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Making Great Strides Toward Filing IND Application for Patented DehydraTECH(TM) Technology

Lexaria has begun the formal process of preparing an application for Investigational New Drug status for DehydraTECH(TM) and cannabidiol for hypertension The filing is being done with the assistance of an outside consultancy group, with Lexaria Bioscience designing non-clinical, clinical, and related product development required prior to the filing – all of which support Lexaria’s more ambitious goals There have been two successful human hypertension trials done with the combination DehydraTECH-CBD therapy in 2021, following an original human clinical study in 2018, and many animal studies Lexaria is making a strong case to support the efficacy of the technology for…

WednesdaySep 15, 2021 11:47 am

Friendable Inc.’s (FDBL) Fan Pass Builds Relationships Between Music Artists & Fans as Platform Grows

Despite the challenges posed by the COVID pandemic during the past year and a half, music artists have continued producing content and fans have increased their efforts to connect with that content Analysts forecast that in the larger entertainment streaming industry, market revenues will grow from the $50 billion recorded early last year to $240 billion by the end of the decade Entertainment technology innovator Friendable Inc. has built a platform to capture a share of the streaming market for music artists, helping artists build their own brands and monetize their performances and content in turn While the pandemic is…

TuesdaySep 14, 2021 2:08 pm

DGE’s 2nd REMS Virtual Summit to Draw Pharmaceutical and Life Science Professionals

Date: October 11-12, 2021 Online Livestream Dynamic Global Events (“DGE”) is proud to announce its 2nd Risk Evaluation and Mitigation Strategies (“REMS”) virtual summit. This two-day event, scheduled for October 11-12, 2021, will be an excellent avenue for life science professionals to develop decision making skills to adapt to anticipate FDA feedback with ease. This virtual conference is an exceptional resource for gaining new insights into adapting to risk mitigation strategies regarding submissions and modifications. DGE has partnered with BioMed Wire, Pharma Voice, Pharma Marketing Networks, and FDA News Watch, among other enterprises, to offer a wholesome experience to event…

TuesdaySep 14, 2021 11:01 am

Ammonia’s Potential as Clean Hydrogen Carrier Illustrates a Key Benefit of FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF) Technology

Canadian-based growth-stage company FuelPositive Corp. is building prototypes for a commercially viable and sustainable clean energy ammonia production system that can enable the hydrogen economy by making the transportation and storage of hydrogen easy and economical Ammonia has been a carbon-intense industry, but FuelPositive’s Phase 2 Hydrogen-Ammonia Synthesizer is a highly portable and scalable patent-pending solution for rolling out a carbon-free, on site production model to end users A report by scientific and technological innovation magazine New Atlas weighs the potential benefits of using ammonia as a means of storing hydrogen for green energy, including ammonia’s ability to “do a…

TuesdaySep 14, 2021 9:46 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Likely to Benefit from New Research Touting Psilocybin Mental Health Treatments

Yale researchers publish study that a single dose of psilocybin counteracts symptoms of depression Administering drug to mice resulted in an approximately 10% increase in neuron size and density Cybin is focused on progressing psychedelic therapeutics As news of psychedelic research continues to report breakthroughs — such as the recent news from a group of Yale researchers that a single dose of psilocybin counteracts symptoms of depression (https://nnw.fm/sMKZC) — companies operating in the space, including Cybin (NEO: CYBN) (NYSE American: CYBN), are ideally positioned to see significant benefits and growth. “Yale researchers found that a single dose of the naturally occurring psychedelic compound psilocybin…

TuesdaySep 14, 2021 9:05 am

SRAX Inc. (NASDAQ: SRAX) Gears up for Its First Ever 2021 Sequire EdTech Conference, Announces EdTech Heavyweights as Keynote Speakers

2021 Sequire EdTech Conference announces keynote speaker lineup and agenda featuring founders and leaders of EdTech big names such as Udemy, HolonIQ, Amesite, and more Online education and remote work sector have exploded over the past years, attracting growing attention from investors Conference aims to bring this growing sector closer to diverse investor audiences, including institutional and retail investors, family offices, venture capitalists and private equity firms, and public and emerging growth companies SRAX (NASDAQ: SRAX), a financial technology company that developed Sequire, a SaaS platform designed to unlock data and insights for publicly traded companies, has announced an impressive…

TuesdaySep 14, 2021 9:00 am

Hypertension: The Silent Killer Making Loud Noise for Investors

NetworkNewsWire Editorial Coverage: Hypertension, or high blood pressure, is rampant in America. An estimated 45% of adults in the United States, or 108 million people, have hypertension, yet only about one out of every four have their condition under control. That’s a big problem considering hypertension increases risks for heart disease and stroke, which are, respectively, the no. 1 and no. 5 leading causes of death in the nation each year. To that point, the CDC names hypertension as a primary or contributing cause in nearly half a million deaths annually in the U.S. Hypertension treatment options vary tremendously from…

TuesdaySep 14, 2021 9:00 am

Digital Media — The Next Generation: AI, Social for Video and Content to Web Ad Commerce

NetworkNewsWire Editorial Coverage: Look a little closer, and it’s clear that the world has entered a major global inflection point in the modern history of digital media. This new era of digital media is set to reshape the future of social fabric and revolutionize how brands connect with their consumers. The increasing innovation and intelligence in digital media tactics and strategies is making consumer messaging amazingly native and relevant. This personable approach to online consumer targeting is providing ways to better serve brands by connecting to current and potential target consumers while cutting through the noise. As recently as 2019,…

MondaySep 13, 2021 2:59 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Impressive Blood Pressure Reduction in Hypertension Clinical Trials

Lexaria Bioscience has developed a patented technology that improves the bioavailability of pharmaceuticals and therapeutics in part by bypassing first-pass-liver processing Lexaria’s patented DehydraTECH (TM) technology is undergoing human clinical trials this year to determine its effectiveness in making cannabidiol (“CBD”) effective as a means of reducing blood pressure for high blood pressure patients The initial results of the first human clinical study showed the DehydraTECH-CBD compound was well tolerated by patients without troubling side effects and that the compound outperformed generic CBD controls Just-released initial (partial) results regarding the compound’s second human clinical trial show that a three-dose regimen…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Month: September 2021